Zacks: Analysts Anticipate Syros Pharmaceuticals, Inc. (SYRS) to Announce -$0.53 Earnings Per Share
Brokerages predict that Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) will post earnings per share (EPS) of ($0.53) for the current quarter, according to Zacks. Zero analysts have made estimates for Syros Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.54) and the highest is ($0.52). Syros Pharmaceuticals reported earnings of ($0.65) per share during the same quarter last year, which indicates a positive year over year growth rate of 18.5%. The company is scheduled to issue its next earnings results on Monday, November 13th.
On average, analysts expect that Syros Pharmaceuticals will report full year earnings of ($2.09) per share for the current year, with EPS estimates ranging from ($2.13) to ($2.00). For the next year, analysts expect that the business will post earnings of ($2.86) per share, with EPS estimates ranging from ($3.79) to ($2.51). Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover Syros Pharmaceuticals.
Syros Pharmaceuticals (NASDAQ:SYRS) last issued its quarterly earnings results on Wednesday, August 9th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.03.
Several equities research analysts have recently weighed in on SYRS shares. ValuEngine cut Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, September 22nd. Zacks Investment Research cut Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, July 19th. JMP Securities raised Syros Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $33.00 price objective for the company in a research report on Thursday, September 28th. Cann reissued a “buy” rating and issued a $28.00 price objective on shares of Syros Pharmaceuticals in a research report on Monday, August 21st. Finally, Cowen and Company reissued a “buy” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, August 9th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $26.14.
In related news, Director Richard A. Young sold 3,282 shares of the firm’s stock in a transaction on Monday, August 14th. The stock was sold at an average price of $22.00, for a total value of $72,204.00. Following the completion of the transaction, the director now directly owns 420,101 shares of the company’s stock, valued at $9,242,222. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Eric R. Olson sold 2,500 shares of the firm’s stock in a transaction on Monday, August 7th. The stock was sold at an average price of $23.59, for a total value of $58,975.00. Following the completion of the transaction, the insider now directly owns 2,500 shares of the company’s stock, valued at $58,975. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 6,332 shares of company stock valued at $140,012. 33.60% of the stock is owned by company insiders.
A number of hedge funds have recently modified their holdings of SYRS. Nationwide Fund Advisors lifted its position in Syros Pharmaceuticals by 249.8% in the second quarter. Nationwide Fund Advisors now owns 7,024 shares of the company’s stock worth $113,000 after purchasing an additional 5,016 shares during the period. The Manufacturers Life Insurance Company raised its stake in Syros Pharmaceuticals by 11,253.8% during the second quarter. The Manufacturers Life Insurance Company now owns 10,559 shares of the company’s stock worth $170,000 after acquiring an additional 10,466 shares in the last quarter. Bank of New York Mellon Corp acquired a new position in Syros Pharmaceuticals during the first quarter worth $185,000. Rhumbline Advisers acquired a new position in Syros Pharmaceuticals during the second quarter worth $198,000. Finally, New York State Common Retirement Fund raised its stake in Syros Pharmaceuticals by 167.9% during the second quarter. New York State Common Retirement Fund now owns 13,400 shares of the company’s stock worth $216,000 after acquiring an additional 8,399 shares in the last quarter. 59.75% of the stock is owned by hedge funds and other institutional investors.
Shares of Syros Pharmaceuticals (NASDAQ:SYRS) traded up 4.75% during mid-day trading on Tuesday, hitting $17.20. 247,458 shares of the company were exchanged. The stock’s market cap is $451.67 million. Syros Pharmaceuticals has a 12-month low of $10.22 and a 12-month high of $24.38. The stock’s 50-day moving average price is $16.10 and its 200 day moving average price is $16.10.
COPYRIGHT VIOLATION NOTICE: “Zacks: Analysts Anticipate Syros Pharmaceuticals, Inc. (SYRS) to Announce -$0.53 Earnings Per Share” was published by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was illegally stolen and republished in violation of US & international copyright and trademark law. The correct version of this story can be read at https://www.americanbankingnews.com/2017/10/31/zacks-analysts-anticipate-syros-pharmaceuticals-inc-syrs-to-announce-0-53-earnings-per-share.html.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.